Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2984017 | 0.92 | HTR7 (0.35) | HTR7TSHRACHE | |
| SCHEMBL2986525 | 0.89 | CYP3A4 (0.38) | TSHRACHE | |
| SCHEMBL3657660 | 0.83 | RAB9A (0.40) | — | |
| SCHEMBL2973523 | 0.82 | KCNH2 (0.42) | — | |
| SCHEMBL2976419 | 0.78 | KCNH2 (0.36) | — | |
| SCHEMBL2976418 | 0.75 | KCNH2 (0.37) | — | |
| SCHEMBL2989532 | 0.72 | BACE1 (0.50) | — | |
| SCHEMBL3660389 | 0.65 | HDAC6 (0.58) | RXFP1TSHR | |
| SCHEMBL2985753 | 0.62 | BACE1 (0.46) | — | |
| SCHEMBL2977803 | 0.61 | TP53 (0.45) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786155-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-08-31 | — | — | US | disclosed |
| EP-2212295-A2 | 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050201-A2 | 4-PHENYL-5-OXO-IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEROF | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099244-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099244-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLC10A6, SLCO1B1 | RXFP1 3910/4885HTR7 1450/4885TSHR 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.